Vinglycinate is a derivative of anticancer drug vinblastine. Vinglycinate was first synthesized in the 1960s and was demonstrated to be a safer alternative to other vinca alkaloids while maintaining comparable activity for the treatment of leukemia in vivo. In clinical trials, administration of vinglycinate resulted in a beneficial response in Hodgkin's disease, lymphosarcoma, bronchogenic carcinoma, and chondrosarcoma. However, to achieve response rates similar to vinblastine, 10-fold higher dose was required, thus making treatment economically unfeasible.